1. The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer

   • Dulcinea Candelaria-Quintana
   • Zoneddy R. Dayao
   • Melanie E. Royce

   Review 11 October 2011 Pages: 355 - 363

2. A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance

   • Catherine Meads
   • Ikhlaaq Ahmed
   • Richard D. Riley

   Review 22 October 2011 Pages: 365 - 377

   

3. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH

   • Simon A. Joosse
   • Kim I. M. Brandwijk
   • Petra M. Nederlof

   Preclinical study 08 July 2010 Pages: 379 - 389

   

4. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer

   • Muralidharan Anbalagan
   • Latonya Carrier
   • Brian G. Rowan

   Preclinical study 21 April 2011 Pages: 391 - 409

   

5. Estrogen receptor-α and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells

   • Jouko Sandholm
   • Joonas H. Kauppila
   • Katri S. Selander

   Preclinical study 24 May 2011 Pages: 411 - 419

   

6. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer

   • Juan Zhang
   • Renguang Pei
   • Yuntao Xie

   Preclinical Study 26 May 2011 Pages: 421 - 428

7. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression

   • Sharon Hensley Alford
   • Katherine Toy
   • Celina G. Kleer

   Preclinical Study 26 May 2011 Pages: 429 - 437

   

8. Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes

   • Jord H. A. Nagel
   • Justine K. Peeters
   • Hanne Meijers-Heijboer

   Preclinical Study 26 May 2011 Pages: 439 - 448

   

9. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells

   • Hagai Ligumsky
   • Ido Wolf
   • Tami Rubinek

   Preclinical Study 03 June 2011 Pages: 449 - 461

   

10. In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer

    • Melanie Spears
    • Karen J. Taylor
    • John M. S. Bartlett

    Preclinical Study 03 June 2011 Pages: 463 - 470

    

11. Bone metastasis in a novel breast cancer mouse model containing human breast and human bone

    • Tian-Song Xia
    • Guo-Zhu Wang
    • Shui Wang

    Preclinical Study 03 June 2011 Pages: 471 - 486

    

12. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways

    • Catherine Ibarra-Drendall
    • Michelle M. Troch
    • Victoria L. Seewaldt

    Preclinical study 07 June 2011 Pages: 487 - 498

    

13. A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity

    • Ensel Oh
    • Yoon-La Choi
    • Young Kee Shin

    Preclinical Study 11 June 2011 Pages: 499 - 509

    

14. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer

    • Jeanette Dupont Jensen
    • Ann Knoop
    • Anne-Vibeke Laenkholm

    Preclinical study 11 June 2011 Pages: 511 - 521

    

15. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse

    • J. Chuck Harrell
    • Aleix Prat
    • Charles M. Perou

    Preclinical Study Open access 14 June 2011 Pages: 523 - 535

    

16. LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome

    • Justin Stebbing
    • Aleksandra Filipovic
    • Georgios Giamas

    Preclinical Study 14 June 2011 Pages: 537 - 544

    

17. The prognostic significance of B lymphocytes in invasive carcinoma of the breast

    • S. M. A. Mahmoud
    • A. H. S. Lee
    • A. R. Green

    Preclinical Study 14 June 2011 Pages: 545 - 553

    

18. The anatomy of fluid-yielding ducts in breast cancer

    • Dominique Twelves
    • Ashutosh Nerurkar
    • Gerald P. H. Gui

    Preclinical study 15 June 2011 Pages: 555 - 564

    

19. Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer

    • Cecilia L. Speyer
    • Jennifer S. Smith
    • David H. Gorski

    Preclinical Study 17 June 2011 Pages: 565 - 573

    

20. Targeting low molecular weight cyclin E (LMW-E) in breast cancer

    • Angela Nanos-Webb
    • Natalie A. Jabbour
    • Khandan Keyomarsi

    Preclinical Study 22 June 2011 Pages: 575 - 588

    

21. Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01

    • Seock-Ah Im
    • Keun Seok Lee
    • Sung Whan Ha

    Clinical trial 18 November 2011 Pages: 589 - 600

    

22. Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors

    • Albane Frati
    • Elisabeth Chereau
    • Roman Rouzier

    Clinical Trial 09 December 2011 Pages: 601 - 607

    

23. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

    • Helen Gogas
    • Urania Dafni
    • George Fountzilas

    Clinical trial 21 December 2011 Pages: 609 - 619

    

24. Absence of ectopic epithelial inclusions in 3,904 axillary lymph nodes examined in sentinel technique

    • Sonja Iken
    • Marcus Schmidt
    • Stephan C. Schaefer

    Clinical Trial 22 December 2011 Pages: 621 - 624

25. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole

    • Shalini Singh
    • Jack Cuzick
    • Anthony Howell

    Clinical trial 25 December 2011 Pages: 625 - 629

26. Outcomes of a weight loss intervention among rural breast cancer survivors

    • Christie A. Befort
    • Jennifer R. Klemp
    • Carol J. Fabian

    Clinical trial 25 December 2011 Pages: 631 - 639

    

27. Cadherin–catenin complex dissociation in lobular neoplasia of the breast

    • Mary Morrogh
    • Victor P. Andrade
    • Tari A. King

    Epidemiology 13 November 2011 Pages: 641 - 652

    

28. Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation

    • Karine Chung
    • Linda J. Hovanessian-Larsen
    • Celeste Leigh Pearce

    Epidemiology Open access 15 November 2011 Pages: 653 - 660

    

29. Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study

    • Pamela Guglielmini
    • Alessandra Rubagotti
    • Francesco Boccardo

    Epidemiology 18 November 2011 Pages: 661 - 668

    

30. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?

    • Shiri Bernholtz
    • Yael Laitman
    • Eitan Friedman

    Epidemiology 24 November 2011 Pages: 669 - 673

31. Surgical treatment of early stage breast cancer in elderly: an international comparison

    • M. Kiderlen
    • E. Bastiaannet
    • G. J. Liefers

    Epidemiology Open access 27 November 2011 Pages: 675 - 682

    

32. Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S.

    • Dana E. Rollison
    • Ashley L. Cole
    • Anna R. Giuliano

    Epidemiology 01 December 2011 Pages: 683 - 691

33. Melatonin pathway genes and breast cancer risk among Chinese women

    • Sandra L. Deming
    • Wei Lu
    • Wei Zheng

    Epidemiology 03 December 2011 Pages: 693 - 699

34. Multilevel determinants of breast cancer survival: association with geographic remoteness and area-level socioeconomic disadvantage

    • Paramita Dasgupta
    • Peter D. Baade
    • Gavin Turrell

    Epidemiology 09 December 2011 Pages: 701 - 710

    

35. A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population

    • Aiko Sueta
    • Hidemi Ito
    • Keitaro Matsuo

    Epidemiology 11 December 2011 Pages: 711 - 721

    

36. Risk of breast cancer in families of multiple affected women and men

    • Melanie Bevier
    • Kristina Sundquist
    • Kari Hemminki

    Epidemiology 17 December 2011 Pages: 723 - 728

    

37. Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project

    • Marilyn L. Kwan
    • Wendy Y. Chen
    • Bette J. Caan

    Epidemiology 21 December 2011 Pages: 729 - 739

    

38. Genetic variants at chromosome 9p21, 10p15 and 10q22 and breast cancer susceptibility in a Chinese population

    • Jiaping Chen
    • Yue Jiang
    • Hongbing Shen

    Epidemiology 25 December 2011 Pages: 741 - 746

39. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer

    • Alberto J. Montero
    • Kiran Avancha
    • Gilberto Lopes

    Brief Report 27 December 2011 Pages: 747 - 751

    

40. Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin

    • Robert C. G. Martin
    • Ken Robbins
    • Ricardo Monaco

    Brief Report 27 December 2011 Pages: 753 - 763

41. Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts

    • Kevin C. Knower
    • Sarah Q. To
    • Colin D. Clyne

    Brief Report 12 January 2012 Pages: 765 - 771